Wegovy and Ozempic contain the same active ingredient, semaglutide, and are injected weekly
Clinical criteria for approval of a PA request for non-preferred lipotropics, omega-3 acids for ASCVD risk reduction are all of the following: If the clinical criteria for non-preferred lipotropics, omega-3 acids for ASCVD risk reduction are met, initial PA requests may be approved for up to 183 days
On the other hand, some concerns to think about for older adults taking GLP-1s include: Dehydration
The impact of stress and stress hormones on endogenous clocks and circadian rhythms
Recent device updates (e.g., Dexcom G7 15-day sensor clearance) further simplify use
There are options ranging from pure ascorbic acid to water-soluble or oil-soluble Vitamin C derivatives